
## **Ronald F Pfeiffer**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2163589/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. Journal of Neurology, 2022, 269, 1335-1352.	1.8	23
2	Gastrointestinal Dysfunction in Parkinson's Disease. Drugs, 2022, 82, 169-197.	4.9	9
3	Movement Disorders and the Gut: A Review. Movement Disorders Clinical Practice, 2022, 9, 418-428.	0.8	3
4	Gastrointestinal dysfunction in the synucleinopathies. Clinical Autonomic Research, 2021, 31, 77-99.	1.4	13
5	Connecting the visual deficit to motor improvement in Parkinson's via art therapy. Parkinsonism and Related Disorders, 2021, 84, 146-147.	1.1	Ο
6	Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3. Parkinsonism and Related Disorders, 2021, 89, 151-154.	1.1	9
7	Consensus on the treatment of dysphagia in Parkinson's disease. Journal of the Neurological Sciences, 2021, 430, 120008.	0.3	23
8	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	5.8	32
9	Autonomic Dysfunction in Parkinson's Disease. Neurotherapeutics, 2020, 17, 1464-1479.	2.1	35
10	Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 76, 63-71.	1.1	39
11	Diagnosing Wilson's Disease under the sword of Damocles. Neurologia I Neurochirurgia Polska, 2020, 54, 364-365.	0.6	2
12	Gastrointestinal Dysfunction in Parkinson's Disease. Current Treatment Options in Neurology, 2018, 20, 54.	0.7	78
13	Neuromuscular rate of force development deficit in Parkinson disease. Clinical Biomechanics, 2017, 45, 14-18.	0.5	25
14	Management of Autonomic Dysfunction in Parkinson's Disease. Seminars in Neurology, 2017, 37, 176-185.	0.5	19
15	Non-motor symptoms in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 22, S119-S122.	1.1	379
16	Differentiating atypical parkinsonian syndromes—a way forward?. Brain and Behavior, 2015, 5, e00341.	1.0	2
17	Levodopa-induced lateral jaw deviation dystonia. Parkinsonism and Related Disorders, 2015, 21, 808.	1.1	6
18	Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurology, The, 2015, 14, 625-639.	4.9	653

RONALD F PFEIFFER

#	Article	IF	CITATIONS
19	Cognitive and Motor Function in Long-Duration <i>PARKIN</i> -Associated Parkinson Disease. JAMA Neurology, 2014, 71, 62.	4.5	49
20	A rare sequence variant in intron 1 of <i><scp>THAP</scp>1</i> is associated with primary dystonia. Molecular Genetics & Genomic Medicine, 2014, 2, 261-272.	0.6	24
21	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. JAMA Neurology, 2014, 71, 543.	4.5	312
22	Neurologic manifestations of malabsorption syndromes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 120, 621-632.	1.0	11
23	Treatment of myoclonus-dystonia syndrome with tetrabenazine. Parkinsonism and Related Disorders, 2014, 20, 1423-1426.	1.1	30
24	Autonomic dysfunction in Parkinson's disease. Expert Review of Neurotherapeutics, 2012, 12, 697-706.	1.4	34
25	Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism and Related Disorders, 2011, 17, 10-15.	1.1	235
26	Wilson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2011, 100, 681-709.	1.0	39
27	Gastrointestinal, urological, and sexual dysfunction in Parkinson's disease. Movement Disorders, 2010, 25, S94-7.	2.2	28
28	Neurologic Presentations of Gastrointestinal Disease. Neurologic Clinics, 2010, 28, 75-87.	0.8	5
29	Nonmotor symptoms in Parkinson disease: the PRIAMO study. Nature Reviews Neurology, 2009, 5, 531-532.	4.9	11
30	Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, 93-100.	1.1	89
31	Non-motor Parkinsonism. Parkinsonism and Related Disorders, 2007, 13, S211-S220.	1.1	29
32	A promising new technology for Parkinson's disease. Neurology, 2005, 65, S6-10.	1.5	30
33	Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurology, The, 2003, 2, 107-116.	4.9	654
34	Potential of Transdermal Drug Delivery in Parkinson??s Disease. Drugs and Aging, 2002, 19, 561-570.	1.3	14
35	Brain meets gut: gastroesophageal reflux. Clinical Autonomic Research, 2001, 11, 3-4.	1.4	1
36	Familial parkinsonism, dementia, and lewy body disease: Study of family G. Annals of Neurology, 1997, 42, 638-643.	2.8	47

3

RONALD F PFEIFFER

#	Article	IF	CITATIONS
37	Constipation in parkinson's disease: Objective assessment and response to psyllium. Movement Disorders, 1997, 12, 946-951.	2.2	190
38	Descriptive Epidemiology of Parkinson's Disease through Proxy Measures. Canadian Journal of Neurological Sciences, 1996, 23, 279-284.	0.3	6
39	Cricopharyngeal dysfunction in Parkinson's disease: Role in dysphagia and response to myotomy. Movement Disorders, 1996, 11, 53-58.	2.2	74
40	Amantadine-induced ?vocal? myoclonus. Movement Disorders, 1996, 11, 104-106.	2.2	37
41	Letters to the editor. Muscle and Nerve, 1996, 19, 109-114.	1.0	0
42	Anorectal function in fluctuating (on-off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography. Movement Disorders, 1995, 10, 650-657.	2.2	72
43	Anorectal manometry in the assessment of anorectal function in Parkinson's disease: A comparison with chronic idiopathic constipation. Movement Disorders, 1994, 9, 655-663.	2.2	61
44	Distribution of cholinergic and dopaminergic receptors in rainbow trout pineal gland. Journal of Pineal Research, 1994, 16, 37-43.	3.4	15
45	Gastrointestinal Dysfunction in Parkinson???s Disease. Journal of Clinical Gastroenterology, 1994, 19, 11-16.	1.1	76
46	Dentatorubro-pallidoluysian atrophy of the myoclonus epilepsy type with posterior column degeneration. Movement Disorders, 1990, 5, 134-138.	2.2	21
47	Clozapine for psychosis in Parkinson's disease. Movement Disorders, 1990, 5, 239-242.	2.2	88
48	CQP 201-403 in Parkinson's disease: An open-label pilot study. Movement Disorders, 1989, 4, 278-281.	2.2	2
49	?On-Off?-induced lethal hyperthermia. Movement Disorders, 1989, 4, 338-341.	2.2	54
50	Cryptococcal meningoencephalitis with parkinsonian features. Movement Disorders, 1988, 3, 271-273.	2.2	15